Chemogenomics knowledgebased polypharmacology analyses of drug abuse related G-protein coupled receptors and their ligands

Frontiers in Pharmacology

Volumn 5 FEB, Issue , 2014, Pages

  Xie, Xiang Qun ^a,b   Wang, Lirong ^a   Liu, Haibin ^a,c   Ouyang, Qin ^a   Fang, Cheng ^a   Su, Weiwei ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemogenomics; Cloud computation; Drug abuse; GPCRs; Polydrug addiction; Polypharmacology; Systems pharmacology; Target prediction

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALPRAZOLAM; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; BUPRENORPHINE; CANNABIDIOL; CARBONATE DEHYDRATASE II; COCAINE; CODEINE; G PROTEIN COUPLED RECEPTOR; LIGAND; METHADONE; NABILONE; NALTREXONE; OPIATE; PENTOBARBITAL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHODIESTERASE V; PROTEIN PDE5A; SECOBARBITAL; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; CANNABIS ADDICTION; CHEMOGENOMICS; COMPUTER MODEL; COMPUTER PROGRAM; DRUG ABUSE; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG TARGETING; FACTUAL DATABASE; GENOMICS; HUMAN; MOLECULAR INTERACTION; OPIATE ADDICTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYPHARMACOLOGY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION;

EID: 84895549657     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00003     Document Type: Article

References (66)

1. Achat-Mendes, C., Platt, D. M., and Spealman, R. D. (2012). Antagonism of metabotropic glutamate 1 receptors attenuates behavioral effects of cocaine and methamphetamine in squirrel monkeys. J. Pharmacol. Exp. Ther. 343, 214-224. doi: 10.1124/jpet.112.196295.
2. Andersen, J. M., Klykken, C., and Mørland, J. (2012). Long-term methadone treatment reduces phosphorylation of CaMKII in rat brain. J. Pharm. Pharmacol. 64, 843-847. doi: 10.1111/j.2042-7158.2012.01469.x.
3. Ashburn, T. T., and Thor, K. B. (2004). Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673-683. doi: 10.1038/nrd1468.
4. Bender, A. (2010). Databases: compound bioactivities go public. Nat. Chem. Biol. 6, 309-309. doi: 10.1038/nchembio.354.
5. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., et al. (2000). The Protein Data Bank. Nucleic Acids Res. 28, 235-242. doi: 10.1093/nar/28.1.235.
6. Brummond, K. M., Goodell, J. R., LaPorte, M. G., Wang, L., and Xie, X.-Q. (2012). Synthesis and in silico screening of a library of β-carboline-containing compounds. Beilstein J. Org. Chem. 8, 1048-1058. doi: 10.3762/bjoc.8.117.
7. Cakmak, H. A., Ikitimur, B., Karadag, B., and Ongen, Z. (2012). An unusual adverse effect of sildenafil citrate: acute myocardial infarction in a nitrate-free patient. BMJ Case Rep. 2012. doi: 10.1136/bcr-2012-006504.
8. CDC. (2014). Prescription Painkiller Overdoses: Methadone. Available online at: http://www.cdc.gov/features/vitalsigns/methadoneoverdoses/.
9. Chen, J. Z., Wang, J., and Xie, X.-Q. (2007). GPCR structure-based virtual screening approach for CB2 antagonist search. J. Chem. Inf. Model. 47, 1626-1637. doi: 10.1021/ci7000814.
10. Collins, F. S. (2010). Opportunities for research and NIH. Science 327, 36. doi: 10.1126/science.1185055.
11. Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., et al. (2012). ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-D1107. doi: 10.1093/nar/gkr777.
12. González, S., Grazia Cascio, M., Fernández-Ruiz, J., Fezza, F., Di Marzo, V., and Ramos, J. A. (2002). Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res. 954, 73-81. doi: 10.1016/S0006-8993(02)03344-9.
13. Granier, S., Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Weis, W. I., et al. (2012). Structure of the delta-opioid receptor bound to naltrindole. Nature 485, 400-404. doi: 10.1038/nature11111.
14. Halpert, A. G., Olmstead, M. C., and Beninger, R. J. (2002). Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci. Biobehav. Rev. 26, 61-67. doi: 10.1016/S0149-7634(01)00038-0.
15. HTDocking. (2013). HTDocking. Identifying Possible Targets for Small Molecules by High Throughput Docking Algorithm. Available online at: http://www.cbligand.org/HTDocking.
16. Jacoby, E. (2011). Computational chemogenomics. Wiley Interdiscip. Rev. Comput. Mol. Sci. 1, 57-67. doi: 10.1002/wcms.11.
17. Kanehisa, M., and Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27-30. doi: 10.1093/nar/28.1.27.
18. Kanehisa, M., Goto, S., Sato, Y., Furumichi, M., and Tanabe, M. (2012). KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 40, D109-D114. doi: 10.1093/nar/gkr988.
19. Kendler, K. S., Schmitt, E., Aggen, S. H., and Prescott, C. A. (2008). Genetic and environmental influences on alcohol, caffeine, cannabis, and nicotine use from early adolescence to middle adulthood. Arch. Gen. Psychiatry 65, 674-682. doi: 10.1001/archpsyc.65.6.674.
20. Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., et al. (2011). DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 39, D1035-D1041. doi: 10.1093/nar/gkq1126.
21. Kroeze, W. K., and Roth, B. L. (2012). "7. Polypharmacological drugs: "Magic Shotguns" for psychiatric diseases," in Polypharmacology in Drug Discovery, ed J.-U. Peters (Hoboken, NJ: John Wiley & Sons, Inc.), 133-148. doi: 10.1002/9781118098141.ch7.
22. Lee, A. M., and Messing, R. O. (2008). Protein kinases and addiction. Ann. N.Y. Acad. Sci. 1141, 22-57. doi: 10.1196/annals.1441.022.
23. Lee, P., and Campbell, L. V. (2008). Diabetic ketoacidosis: the usual villain or a scapegoat? A novel cause of severe metabolic acidosis in type 1 diabetes. Diabetes Care 31, e13. doi: 10.2337/dc07-2143.
24. Lee, P., Greenfield, J. R., and Campbell, L. V. (2008). "Mind the gap" when managing ketoacidosis in type 1 diabetes. Diabetes Care 31, e58. doi: 10.2337/dc08-0690.
25. Lee, P., Greenfield, J. R., and Campbell, L. V. (2009). Managing young people with Type 1 diabetes in a 'rave' new world: metabolic complications of substance abuse in Type 1 diabetes. Diabet. Med. 26, 328-333. doi: 10.1111/j.1464-5491.2009.02678.x.
26. Lee, P., Greenfield, J. R., Gilbert, K., and Campbell, L. V. (2012). Recreational drug use in type 1 diabetes: an invisible accomplice to poor glycaemic control? Intern. Med. J. 42, 198-202. doi: 10.1111/j.1445-5994.2011.02653.x.
27. Lee, P., Nicoll, A. J., McDonough, M., and Colman, P. G. (2005). Substance abuse in young patients with type 1 diabetes: easily neglected in complex medical management. Intern. Med. J. 35, 359-361. doi: 10.1111/j.1445-5994.2005.00814.x.
28. Li, C. Y., Mao, X., and Wei, L. (2008). Genes and (common) pathways underlying drug addiction. PLoS Comput. Biol. 4:e2. doi: 10.1371/journal.pcbi.0040002.
29. Li, K., and Xu, E. (2008). The role and the mechanism of gamma-aminobutyric acid during central nervous system development. Neurosci. Bull. 24, 195-200. doi: 10.1007/s12264-008-0109-3.
30. Ma, C., Wang, L., and Xie, X.-Q. (2011a). GPU accelerated chemical similarity calculation for compound library comparison. J. Chem. Inf. Model. 51, 1521-1527. doi: 10.1021/ci1004948.
31. Ma, C., Wang, L., and Xie, X.-Q. (2011b). Ligand classifier of adaptively boosting ensemble decision stumps (LiCABEDS) and its application on modeling ligand functionality for 5HT-subtype GPCR families. J. Chem. Inf. Model. 51, 521-531. doi: 10.1021/ci100399j.
32. Ma, C., Wang, L., Yang, P., Tong, Q., Myint, K. Z., and Xie, X.-Q. (2013). LiCABEDS II. Modeling of ligand selectivity for G-protein coupled cannabinoid receptors. J. Chem. Inf. Model. 53, 11-26. doi: 10.1021/ci3003914.
33. Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., et al. (2012). Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 485, 321-326. doi: 10.1038/nature10954.
34. Martin, Y. C., Kofron, J. L., and Traphagen, L. M. (2002). Do structurally similar molecules have similar biological activity? J. Med. Chem. 45, 4350-4358. doi: 10.1021/jm020155c.
35. Morales, M., and Bonci, A. (2012). Getting to the core of addiction: hooking CB2 receptor into drug abuse? Nat. Med. 18, 504-505. doi: 10.1038/nm.2722.
36. Morphy, R. (2012). "12. Selective multitargeted drugs," in Polypharmacology in Drug Discovery, ed J.-U. Peters (Hoboken, NJ: John Wiley & Sons, Inc.), 247-262. doi: 10.1002/9781118098141.ch12.
37. Morphy, R., Kay, C., and Rankovic, Z. (2004). From magic bullets to designed multiple ligands. Drug Discov. Today 9, 641-651. doi: 10.1016/S1359-6446(04)03163-0.
38. Myint, K.-Z., Wang, L., Tong, Q., and Xie, X.-Q. (2012). Molecular fingerprint-based artificial neural networks QSAR for ligand biological activity predictions. Mol. Pharm. 9, 2912-2923. doi: 10.1021/mp300237z.
39. Nestler, E. J. (2001). Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci. 2, 119-128. doi: 10.1038/35053570.
40. Nestler, E. J., and Malenka, R. C. (2004). The addicted brain. Sci. Am. 290, 78-85. doi: 10.1038/scientificamerican0304-78.
41. Nissen, S. E., and Wolski, K. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471. doi: 10.1056/NEJMoa072761.
42. Oprea, T. I., Bauman, J. E., Bologa, C. G., Buranda, T., Chigaev, A., Edwards, B. S., et al. (2011). Drug repurposing from an academic perspective. Drug Discov. Today Ther. Strateg. 8, 61-69. doi: 10.1016/j.ddstr.2011.10.002.
43. Peters, J.-U. (ed.). (2012). Polypharmacology in Drug Discovery. Hoboken, NJ: John Wiley & Sons, Inc.
44. Pozzan, A. (2006). Molecular descriptors and methods for ligand based virtual high throughput screening in drug discovery. Curr. Pharm. Des. 12, 2099-2110. doi: 10.2174/138161206777585247.
45. Prenatal Exposure to Drugs of Abuse. (2011). NIDA Topics in Brief. Available online at: http://www.drugabuse.gov/publications/topics-in-brief/prenatal-exposure-to-drugs-abuse.
46. Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 264, 2511-2518. doi: 10.1001/jama.1990.03450190043026.
47. Ricardo Buenaventura, M., Rajive Adlaka, M., and Nalini Sehgal, M. (2008). Opioid complications and side effects. Pain Physician 11, S105-S120.
48. Roth, D. E., Venta, P. J., Tashian, R. E., and Sly, W. S. (1992). Molecular basis of human carbonic anhydrase II deficiency. Proc. Natl. Acad. Sci. U.S.A. 89, 1804-1808. doi: 10.1073/pnas.89.5.1804.
49. Saccone, S. F., Bierut, L. J., Chesler, E. J., Kalivas, P. W., Lerman, C., Saccone, N. L., et al. (2009). Supplementing high-density SNP microarrays for additional coverage of disease-related genes: addiction as a paradigm. PLoS ONE 4:e5225. doi: 10.1371/journal.pone.0005225.
50. Saccone, S. F., Saccone, N. L., Swan, G. E., Madden, P. A., Goate, A. M., Rice, J. P., et al. (2008). Systematic biological prioritization after a genome-wide association study: an application to nicotine dependence. Bioinformatics 24, 1805-1811. doi: 10.1093/bioinformatics/btn315.
51. SAMHSA. (2009). Substance Abuse and Mental Health Services Administration. Center for Substance Abuse Treatment. Available online at: http://nac.samhsa.gov/dtab/docs/dtab6.2.09transcript508.pdf. Rockville, MD 20857.
52. Sankararaman, A., Masiulis, I., Richardson, D. R., Andersen, J. M., Mørland, J., and Eisch, A. J. (2012). Methadone does not alter key parameters of adult hippocampal neurogenesis in the heroin-naïve rat. Neurosci. Lett. 516, 99-104. doi: 10.1016/j.neulet.2012.03.066.
53. Silfies, P. J., and DeMicco, F. J. (2013). Impact of substance abuse: human resource strategies for the hospitality industry. Hospital. Rev. 10:9.
54. Spiller, H. A., James, K. J., Scholzen, S., and Borys, D. J. (2013). A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding. Subst. Abus. 34, 306-312. doi: 10.1080/08897077.2013.772083.
55. Tandon, M., Wang, L., Xu, Q., Xie, X., Wipf, P., and Wang, Q. J. (2012). A targeted library screen reveals a new inhibitor scaffold for protein kinase D. PLoS ONE 7:e44653. doi: 10.1371/journal.pone.0044653.
56. Thompson, A. A., Liu, W., Chun, E., Katritch, V., Wu, H., Vardy, E., et al. (2012). Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 485, 395-399. doi: 10.1038/nature11085.
57. Wang, L., Ma, C., Wipf, P., Liu, H., Su, W., and Xie, X.-Q. (2013). TargetHunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database. AAPS J. 15, 395-406. doi: 10.1208/s12248-012-9449-z.
58. Wang, L., and Xie, X.-Q. (2010). An Online Blood-brain Barrier Predictor (fBBB) Based on Molecular Fingerprints. Available online at: http://www.cbligand.org/BBB/.
59. Winters, B. D., Kruger, J. M., Huang, X., Gallaher, Z. R., Ishikawa, M., Czaja, K., et al. (2012). Cannabinoid receptor 1-expressing neurons in the nucleus accumbens. Proc. Natl. Acad. Sci. U.S.A. 109, E2717-E2725. doi: 10.1073/pnas.1206303109.
60. Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., et al. (2008). DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36, D901-D906. doi: 10.1093/nar/gkm958.
61. Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard, P., et al. (2006). DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, D668-D672. doi: 10.1093/nar/gkj067.
62. Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G. W., Vardy, E., et al. (2012). Structure of the human kappa-opioid receptor in complex with JDTic. Nature 485, 327-332. doi: 10.1038/nature10939.
63. Xi, Z. X., Peng, X.-Q., Li, X., Song, R., Zhang, H. Y., Liu, Q. R., et al. (2011). Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. Nat. Neurosci. 14, 1160-1166. doi: 10.1038/nn.2874.
64. Xie, X.-Q., and Chen, J. Z. (2008). Data mining a small molecule drug screening representative subset from NIH PubChem. J. Chem. Inf. Model. 48, 465-475. doi: 10.1021/ci700193u.
65. Xie, X.-Q. S. (2010). Exploiting PubChem for virtual screening. Expert Opin. Drug Discov. 5, 1205-1220. doi: 10.1517/17460441.2010.524924.
66. Yang, P., Wang, L., and Xie, X.-Q. (2012). Latest advances in novel cannabinoid CB2 ligands for drug abuse and their therapeutic potential. Future Med. Chem. 4, 187-204. doi: 10.4155/fmc.11.179.